The HR−/HER2+ subtype had a reduced risk of axillary lymph node metastasis as compared to the HR+/HER2+ subtype, with an OR of 0.779 (95 % CI: 0.609–0.997, P = 0.048). The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.